These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 21386708

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Levosimendan: beyond its simple inotropic effect in heart failure.
    Antoniades C, Tousoulis D, Koumallos N, Marinou K, Stefanadis C.
    Pharmacol Ther; 2007 May; 114(2):184-97. PubMed ID: 17363065
    [Abstract] [Full Text] [Related]

  • 3. Levosimendan: implications for clinicians.
    McBride BF, White CM.
    J Clin Pharmacol; 2003 Oct; 43(10):1071-81. PubMed ID: 14517189
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Levosimendan: a new option in acute cardiac failure.
    Holley AD, Ziegenfuss M.
    Emerg Med Australas; 2006 Oct; 18(5-6):505-9. PubMed ID: 17083641
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Levosimendan in patients with low-output heart failure: lessons from the LIDO trial.
    Follath F.
    Ital Heart J; 2003 May; 4 Suppl 2():34S-38S. PubMed ID: 14635368
    [Abstract] [Full Text] [Related]

  • 9. Levosimendan, a new calcium-sensitizing inotrope for heart failure.
    Ng TM.
    Pharmacotherapy; 2004 Oct; 24(10):1366-84. PubMed ID: 15628834
    [Abstract] [Full Text] [Related]

  • 10. Levosimendan and calcium sensitization of the contractile proteins in cardiac muscle: impact on heart failure.
    Kota B, Prasad AS, Economides C, Singh BN.
    J Cardiovasc Pharmacol Ther; 2008 Dec; 13(4):269-78. PubMed ID: 19087950
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Levosimendan: first in a new class of inodilator for acute and chronic severe heart failure.
    Cleland JG, Nikitin N, McGowan J.
    Expert Rev Cardiovasc Ther; 2004 Jan; 2(1):9-19. PubMed ID: 15038409
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Levosimendan. Clinical indications of a new vasoactive substance].
    Braun JP, Döpfmer U, Kastrup M, Roots I, Borges A, Schneider M, Dohmen P, Kox W, Spies C.
    Anaesthesist; 2004 Feb; 53(2):163-7. PubMed ID: 14991194
    [Abstract] [Full Text] [Related]

  • 18. Is calcium sensitization the best strategy to improve myocardial contractility in acute heart failure?
    Erhardt LR.
    Ital Heart J; 2003 May; 4 Suppl 2():27S-33S. PubMed ID: 14635367
    [Abstract] [Full Text] [Related]

  • 19. Levosimendan: dual mechanisms for acute heart failure...and beyond?
    Ng TM, Akhter MW.
    Minerva Cardioangiol; 2005 Dec; 53(6):565-84. PubMed ID: 16333239
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.